BACKGROUND: We aimed to develop an actionable and feasible prospective clinical model to estimate toxicity risk to assist chimeric antigen receptor (CAR) T-cell therapy providers with the management of patients with relapsed and/or refractory large B...
OBJECTIVE: This study developed and validated a deep learning model based on clinical and histopathological features for predicting the outcomes of diffuse large B-cell lymphoma (DLBCL).
M2 macrophages play a crucial role in the initiation and progression of various tumors, including diffuse large B-cell lymphoma (DLBCL). However, the characterization of M2 macrophage-related genes in DLBCL remains incomplete. In this study, we downl...
The Journal of international medical research
Apr 25, 2025
ObjectiveOur objective was to investigate a novel cancer-associated fibroblast-related gene signature for predicting clinical outcomes in patients with diffuse large B cell lymphoma.MethodsThe cancer-associated fibroblast-related module genes were id...
Multiple machine learning techniques were employed to identify key long non-coding RNA (lncRNA) biomarkers associated with cuproptosis in Diffuse Large B-Cell Lymphoma (DLBCL). Data from the TCGA and GEO databases facilitated the identification of 12...
International journal of radiation oncology, biology, physics
Apr 3, 2025
PURPOSE: Bridging radiation therapy (BRT) is effective for local control in patients with relapsed or refractory large B cell lymphoma who are undergoing chimeric antigen receptor (CAR) T cell therapy. We hypothesized that adaptive BRT (ABRT), which ...
Journal of cancer research and clinical oncology
Mar 28, 2025
PURPOSE: To explore the development and validation of automated machine learning (AutoML) models for F-FDG PET imaging-based radiomics signatures to predict treatment response in elderly patients with diffuse large B-cell lymphoma (DLBCL).
Clinical lymphoma, myeloma & leukemia
Feb 20, 2025
BACKGROUND: Anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising treatment for large B-cell lymphoma (LBCL); however, durable complete responses are achieved in only 30% to 40% of patients. Additionally, CAR-T therapy...
BACKGROUND AND OBJECTIVE: Positron emission tomography/computed tomography (PET/CT) is recommended as the standard imaging modality for diffuse large B-cell lymphoma (DLBCL) staging. However, many studies have neglected the role of patients' prognost...
International journal of biological macromolecules
Oct 31, 2024
Ferroptosis has emerged as a critical mechanism in the development and progression of various tumors, particularly diffuse large B-cell lymphoma (DLBCL). However, the thorough characterization of ferroptosis-related genes in DLBCL remains inadequatel...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.